<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03859466</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-HEART-001</org_study_id>
    <nct_id>NCT03859466</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting</brief_title>
  <acronym>CAST-HF</acronym>
  <official_title>Safety and Efficacy of Cardiac Shockwave Therapy in Patients Undergoing Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Efficacy of Cardiac Shockwave Therapy (CAST-HF) in patients undergoing coronary
      artery bypass grafting
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the safety and performance characteristics of the Direct Epicardial
      Shockwave Therapy System (DESWT) as applied with the Cardiac Shockwave Probe (CSP).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study investigates the safety and performance characteristics of the Direct Epicardial Shockwave Therapy System (DESWT) as applied with the Cardiac Shockwave Probe (CSP) vs. Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of related adverse events (Safety) and differences in LVEF (Efficacy) with in one week</measure>
    <time_frame>7 days</time_frame>
    <description>To assess the safety profile of the device (number of related adverse events, control vs. treatment group) To assess the Improvement of LVEF after treatment (control vs. treatment group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of related adverse events (Safety) and differences in LVEF (Efficacy) with in one year</measure>
    <time_frame>360 days</time_frame>
    <description>To assess the safety profile of the device (number of related adverse events, control vs. treatment group over a period of 1 year) To assess the Improvement of LVEF after treatment (control vs. treatment group over a period of 1 year)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Heart Failure Patients</condition>
  <arm_group>
    <arm_group_label>Intervention Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information: This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>For each of this packages exactly half of the envelops will be filled with control (20/40) or intervention (20/40) information This is a prospective, single-blind, randomized, single-centre study. The investigational medicinal product (shockwave therapy) to which individual patients will be assigned is determined by a randomised schedule with a 1:1 allocation ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shockwave Therapy</intervention_name>
    <description>Surgically invasive device, transient use only for the time of surgical intervention, intended for use in direct contact with the heart, intended to correct defect of the heart.
Throughout the study, investigators are permitted to use their clinical judgement when prescribing concomitant medications and treatments for trial patients. Local prescribing information and institutional guidelines should be followed as applicable</description>
    <arm_group_label>Intervention Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients above 21 and under 90 years of age undergoing primary coronary
             artery bypass grafting.

          -  Patients have to present with reduced left ventricular function defined as LVEF ≤ 40%.

          -  Patients have to present with regional left ventricular wall motion abnormalities.

          -  Patients have to give written informed consent to participate in the study.

        Exclusion Criteria:

          -  Significant concomitant valve disease in need of surgical treatment (Except
             significant valve disease not detected in preoperative cardiac ultrasound that is
             detected intra-operatively).

          -  HIV positive patients

          -  Hepatitis C positive patients

          -  A baseline glomerular filtration rate &lt;50 ml/min/1.73m2

          -  Serious radiographic contrast allergy.

          -  Patients in cardiogenic shock.

          -  Patients with a contraindication for cardiac MRI.

          -  History of significant ventricular arrhythmias, except arrhythmias associated with MI.

          -  Present co-morbidity which reduces life expectancy to less than 1 year.

          -  Presence of ventricular thrombus

          -  Presence of a cardiac tumor

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johannes Holfeld</last_name>
    <phone>+43 0512 504 80800</phone>
    <email>johannes.holfeld@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Can Gollmann-Tepeköylü</last_name>
    <phone>+43 0512 504 80466</phone>
    <email>can.gollmann-tepekoeylue@tirol-kliniken.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Innsbruck - Competence Center for Clinical Trials</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nihad Muric</last_name>
      <phone>+43 0512 9003 70085</phone>
      <email>nihad.muric@i-med.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Embacher-Aichhorn</last_name>
      <phone>+43 0512 9003 70085</phone>
      <email>sabine.embacher@i-med.ac.at</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

